PEPTIDE GUARDIANResearch literacy for peptides

Compounds / Metabolic

Semaglutide

Also written as: Ozempic, Wegovy, Rybelsus, NN9535, NNC 0113-0217, GLP-1 receptor agonist

Known for
Best known as an approved weight-loss and diabetes medicine.
What studies show
In the main obesity trial, 1,961 adults lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo; in a 327-person follow-up, about two-thirds of the loss was regained a year after stopping.

Semaglutide is a man-made version of the gut hormone GLP-1; it is an FDA-approved prescription medicine backed by some of the largest trials in this field, but the compounded, salt-form and "research use" versions sold online are not that approved medicine.

Where the evidence stands

  1. 1 of 4Animal and cell studies only
  2. 2 of 4Early human trials
  3. 3 of 4Late-stage human trials
  4. 4 of 4Approved medicine

The short version

  • It is an approved prescription medicine in the United States: Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight reduction and for lowering heart risk.
  • In the main obesity trial, 1,961 adults lost an average of 14.9% of their body weight over 68 weeks, against 2.4% with placebo.
  • In a trial of 17,604 adults with heart disease and overweight or obesity, heart attack, stroke or cardiovascular death occurred in 6.5% on semaglutide and 8.0% on placebo.
  • Weight came back after stopping. One year after treatment ended, people had regained about two-thirds of the weight they had lost.
  • Nausea, diarrhea, vomiting and constipation are common. All the labels carry a boxed warning about thyroid tumors seen in rodents, and in November 2026 the FDA required a new warning about a rare eye condition.
  • Compounded and "research use" semaglutide are not FDA-approved. The FDA says salt forms such as semaglutide sodium are different ingredients with no known lawful basis for compounding.
  • It is not banned in sport, but the World Anti-Doping Agency has monitored it since 2024.

What it is

Semaglutide is a modified peptide. A peptide is a short chain of amino acids, the building blocks of proteins. It is a close copy of a natural gut hormone called GLP-1 (glucagon-like peptide-1). The FDA label describes it as a GLP-1 receptor agonist. A receptor is a docking site on a cell, and an agonist is a substance that switches a receptor on.

More on what it is and where it came from

In the United States it is a prescription medicine made by Novo Nordisk and sold under three brand names. Ozempic (an injection, approved December 5, 2017) and Rybelsus (a tablet, approved September 20, 2019) are approved for adults with type 2 diabetes. Ozempic's label also covers lowering the risk of major heart events in adults with type 2 diabetes and heart disease, and lowering the risk of worsening kidney disease in adults with type 2 diabetes and chronic kidney disease. Wegovy (an injection approved June 4, 2021, and a tablet approved December 22, 2025) is approved to reduce excess body weight and keep it off, and to lower the risk of major heart events in adults with heart disease and obesity or overweight. The Wegovy injection is also approved, under the FDA's accelerated pathway, for a serious fatty liver disease called MASH with liver scarring.

All of these labels carry a boxed warning, the FDA's strongest type, about thyroid C-cell tumors seen in rodents. Semaglutide is also sold as compounded products and as unapproved powder labeled "for research use only". The FDA has said these products are not FDA-approved, has warned sellers, and has said that salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved medicines. Nothing on this page is advice about using any form of semaglutide.

Semaglutide was designed by scientists at Novo Nordisk in Denmark. A 2015 paper in the Journal of Medicinal Chemistry described how they started from liraglutide, an older GLP-1 medicine, and changed the molecule so that it held on to albumin (a common blood protein) more tightly and resisted breakdown in the body. Large phase 3 trial programs followed, including SUSTAIN (injection, type 2 diabetes), STEP (injection, obesity) and OASIS (tablet, obesity). The FDA first approved it in December 2017.

How it is thought to work

According to the FDA labels, semaglutide binds to and activates the GLP-1 receptor, the same target as the body's own GLP-1. It is 94% identical to human GLP-1. In people with type 2 diabetes it increased the release of insulin and lowered the hormone glucagon, in both cases only when blood sugar was raised. It also caused a delay in the emptying of the stomach. The Wegovy label says it lowers calorie intake, likely by affecting appetite.

More on how it works

The molecule differs from natural GLP-1 in three ways, described in the FDA label and the 2015 discovery paper. One amino acid near the start of the chain was swapped so that an enzyme called DPP-4 cannot break it down quickly. A fatty acid chain was attached through a spacer to a lysine (one of the amino acids), which lets the molecule bind to albumin in the blood. One further amino acid was changed so that only one fatty chain attaches. The label says albumin binding is the main reason it lasts so long: more than 99% of it is bound to albumin in the blood and its half-life (the time for the blood level to fall by half) is about one week.

Very little semaglutide is absorbed when swallowed. The tablets contain an absorption helper called salcaprozate sodium (SNAC), and the Rybelsus label puts the share of the tablet that reaches the blood at roughly 0.4% to 1%. For the injection the figure is 89%.

What is established in people

Semaglutide is one of the most heavily studied medicines of its kind. Large randomized trials showed that it lowers body weight (about 15% on average over 68 weeks in adults with obesity), and that it lowered the rate of heart attack, stroke or cardiovascular death in people who already had heart disease, and of worsening kidney disease in people with type 2 diabetes and kidney disease. What is less settled: most of the lost weight returned within a year of stopping, a liver disease approval rests on interim biopsy results, and two large trials found no benefit in early Alzheimer's disease. Nearly all of these trials were paid for by the maker, and none tested compounded, salt-form or "research use" products.

What the studies found

12 studies, human trials first. Each links to the paper or registry record.

  1. Human trial2026

    Efficacy and safety of oral semaglutide [dose omitted here] (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials

    Semaglutide did not slow the disease.

    Full finding, who was studied, and limits

    Who: 3,808 people aged 55 to 85 with early Alzheimer's disease confirmed by amyloid testing (mild cognitive impairment or mild dementia), in two trials at 566 sites in 40 countries. Randomly assigned to semaglutide tablets or placebo. The main result was measured at 104 weeks.

    Semaglutide did not slow the disease. On the main rating scale of memory and daily function (CDR-SB, where a higher score is worse), scores worsened by 2.3 points in both groups in one trial, and by 2.2 points with semaglutide against 2.1 with placebo in the other. Neither difference was statistically significant. The trials were stopped after this result. Adverse events during treatment were reported by 91.2% on semaglutide and 84.8% on placebo.

    Read with care: A clear negative result from two large trials. It tested the tablet form in people who already had early Alzheimer's disease, so it does not directly answer whether semaglutide affects the risk of developing dementia. Funded by Novo Nordisk.

    The Lancet (evoke NCT04777396 and evoke+ NCT04777409) · pubmed.ncbi.nlm.nih.gov

  2. Human trial2025

    Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes

    Major cardiovascular events occurred in 12.0% of the semaglutide tablet group (579 people) and 13.8% of the placebo group (668 people), a hazard ratio of 0.86 (95% confidence interval 0.77 to 0.96).

    Full finding, who was studied, and limits

    Who: 9,650 adults aged 50 or older with type 2 diabetes and known heart or blood vessel disease, chronic kidney disease, or both. Randomly assigned to semaglutide tablets (4,825) or placebo (4,825) on top of standard care. Double-blind. Average follow-up was 47.5 months.

    Major cardiovascular events occurred in 12.0% of the semaglutide tablet group (579 people) and 13.8% of the placebo group (668 people), a hazard ratio of 0.86 (95% confidence interval 0.77 to 0.96). Serious adverse events were reported in 47.9% and 50.3%. The planned secondary outcomes, including major kidney disease events, did not differ significantly between groups.

    Read with care: The benefit was smaller than in the injection trials, and the kidney outcome was not improved. Everyone had type 2 diabetes and was already at high risk. Funded by Novo Nordisk.

    New England Journal of Medicine (SOUL, NCT03914326) · pubmed.ncbi.nlm.nih.gov

  3. Human trial2025

    Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis

    The liver inflammation resolved, without the scarring getting worse, in 62.9% on semaglutide and 34.3% on placebo.

    Full finding, who was studied, and limits

    Who: A planned interim analysis of the first 800 of 1,197 patients with biopsy-confirmed MASH (a serious fatty liver disease) and moderate to advanced liver scarring: 534 on injected semaglutide and 266 on placebo, assessed at 72 weeks. The full trial is planned to run for 240 weeks.

    The liver inflammation resolved, without the scarring getting worse, in 62.9% on semaglutide and 34.3% on placebo. Scarring improved, without the inflammation getting worse, in 36.8% and 22.4%. Average weight change was -10.5% against -2.0%. Stomach and gut side effects were more common with semaglutide.

    Read with care: These are biopsy results at an interim point, not proof of fewer liver transplants, liver failures or deaths. The FDA approval for this use is an accelerated approval that depends on the rest of the trial confirming a benefit. Funded by Novo Nordisk.

    New England Journal of Medicine (ESSENCE, NCT04822181) · pubmed.ncbi.nlm.nih.gov

  4. Human trial2025

    Oral Semaglutide at a Dose of [dose omitted here] in Adults with Overweight or Obesity

    Average weight change at week 64 was -13.6% with semaglutide tablets and -2.2% with placebo, a difference of 11.4 percentage points.

    Full finding, who was studied, and limits

    Who: 307 adults with obesity, or overweight with a weight-related condition, and without diabetes. Randomly assigned to semaglutide tablets (205) or placebo (102), both with lifestyle support. Double-blind, 22 sites in four countries, 71 weeks in total with the main result at week 64.

    Average weight change at week 64 was -13.6% with semaglutide tablets and -2.2% with placebo, a difference of 11.4 percentage points. Stomach and gut side effects were reported by 74.0% on the tablets and 42.2% on placebo.

    Read with care: A small trial compared with the injection trials. Three in four people on the tablets had stomach or gut side effects. Funded by Novo Nordisk. The FDA label reports the placebo figure as -2.4%, a small difference that probably reflects a different method of analysis.

    New England Journal of Medicine (OASIS 4, NCT05564117) · pubmed.ncbi.nlm.nih.gov

  5. Human trial2025

    Once-weekly semaglutide [dose omitted here] in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial

    Average weight change at 72 weeks was -18.7% with the higher dose, -15.6% with the standard dose and -3.9% with placebo.

    Full finding, who was studied, and limits

    Who: 1,407 adults with a BMI of 30 or more and without diabetes. Randomly assigned to a higher dose of injected semaglutide (1,005), the standard approved dose (201) or placebo (201) for 72 weeks, all with lifestyle support. Double-blind, 95 sites in 11 countries.

    Average weight change at 72 weeks was -18.7% with the higher dose, -15.6% with the standard dose and -3.9% with placebo. Stomach and gut side effects were reported by 70.8%, 61.2% and 42.8%. Dysaesthesia (altered skin sensation such as tingling, sensitivity or burning) was reported by 22.9%, 6.0% and 0.5%. Serious adverse events were reported by 6.8%, 10.9% and 5.5%. In a companion trial in 512 adults with obesity and type 2 diabetes, weight change was -13.2% with the higher dose against -3.9% with placebo.

    Read with care: The extra weight loss over the standard dose was about 3 percentage points, and it came with more gut side effects and a clear rise in altered skin sensation. The FDA has said it is investigating that side effect further. Funded by Novo Nordisk.

    The Lancet Diabetes & Endocrinology (STEP UP, NCT05646706) · pubmed.ncbi.nlm.nih.gov

  6. Human trial2024

    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes

    Major kidney disease events (kidney failure, loss of at least half of kidney function, or death from kidney or cardiovascular causes) occurred as a first event in 331 people on semaglutide and 410 on placebo, a hazard ratio of 0.76 (95% confidence interval 0.66 to 0.88).

    Full finding, who was studied, and limits

    Who: 3,533 adults with type 2 diabetes and chronic kidney disease, randomly assigned to injected semaglutide (1,767) or placebo (1,766). Median follow-up was 3.4 years. The trial was stopped early after a planned interim analysis.

    Major kidney disease events (kidney failure, loss of at least half of kidney function, or death from kidney or cardiovascular causes) occurred as a first event in 331 people on semaglutide and 410 on placebo, a hazard ratio of 0.76 (95% confidence interval 0.66 to 0.88). Death from any cause was also lower (hazard ratio 0.80, 95% confidence interval 0.67 to 0.95). Serious adverse events were reported in 49.6% on semaglutide and 53.8% on placebo.

    Read with care: All participants had both type 2 diabetes and kidney disease, so the result does not apply to kidney disease without diabetes. Trials stopped early can overstate the size of a benefit. Funded by Novo Nordisk.

    New England Journal of Medicine (FLOW, NCT03819153) · pubmed.ncbi.nlm.nih.gov

  7. Human trial2023

    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

    Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% of the semaglutide group (569 people) and 8.0% of the placebo group (701 people), a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90).

    Full finding, who was studied, and limits

    Who: 17,604 adults aged 45 or older with existing heart or blood vessel disease and a BMI of 27 or more, with no history of diabetes. Randomly assigned to injected semaglutide (8,803) or placebo (8,801). Double-blind. Average follow-up was 39.8 months.

    Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.5% of the semaglutide group (569 people) and 8.0% of the placebo group (701 people), a hazard ratio of 0.80 (95% confidence interval 0.72 to 0.90). Side effects led 16.6% on semaglutide and 8.2% on placebo to stop treatment for good.

    Read with care: This is the largest semaglutide trial found. Everyone in it already had heart or blood vessel disease, so it does not show a heart benefit for people with obesity alone. About one in six people on semaglutide stopped because of side effects. Funded by Novo Nordisk.

    New England Journal of Medicine (SELECT, NCT03574597) · pubmed.ncbi.nlm.nih.gov

  8. Human trial2022

    Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

    In this group, average weight loss at week 68 had been 17.3% with semaglutide and 2.0% with placebo.

    Full finding, who was studied, and limits

    Who: 327 of the STEP 1 participants, followed for one more year after both the drug and the lifestyle support were stopped at week 68.

    In this group, average weight loss at week 68 had been 17.3% with semaglutide and 2.0% with placebo. One year after stopping, the semaglutide group had regained 11.6 percentage points, about two-thirds of what they had lost, leaving a net loss of 5.6% from the start. Improvements in measures such as blood pressure and blood sugar had moved back toward their starting levels for most measures.

    Read with care: This tempers the headline weight-loss numbers. It covers a subset of trial completers, and the authors describe all extension analyses as exploratory. Lifestyle support was withdrawn at the same time as the drug.

    Diabetes, Obesity and Metabolism (STEP 1 extension, NCT03548935) · pubmed.ncbi.nlm.nih.gov

  9. Human trial2021

    Once-Weekly Semaglutide in Adults with Overweight or Obesity

    Average weight change at 68 weeks was -14.9% with semaglutide and -2.4% with placebo (-15.3 kg against -2.6 kg).

    Full finding, who was studied, and limits

    Who: 1,961 adults with a body mass index (BMI) of 30 or more, or 27 or more with at least one weight-related condition, and without diabetes. Randomly assigned 2 to 1 to injected semaglutide or placebo for 68 weeks, both with lifestyle support. Double-blind.

    Average weight change at 68 weeks was -14.9% with semaglutide and -2.4% with placebo (-15.3 kg against -2.6 kg). At least 5% of body weight was lost by 86.4% on semaglutide and 31.5% on placebo; at least 10% by 69.1% and 12.0%; at least 15% by 50.5% and 4.9%. Nausea and diarrhea were the most common side effects. Stomach and gut side effects led 4.5% on semaglutide and 0.8% on placebo to stop treatment.

    Read with care: Funded by Novo Nordisk. People with diabetes were excluded. Everyone also received lifestyle support. The 68-week result says nothing about what happens after stopping (see STEP 4 and the STEP 1 extension below).

    New England Journal of Medicine (STEP 1, NCT03548935) · pubmed.ncbi.nlm.nih.gov

  10. Human trial2021

    Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial

    During the 20-week run-in, average weight fell by 10.6%.

    Full finding, who was studied, and limits

    Who: 902 adults with obesity or overweight (no diabetes) took semaglutide for a 20-week run-in. The 803 who reached the target dose were then randomly assigned to continue semaglutide (535) or switch to placebo (268) for 48 more weeks, without knowing which. 73 sites in 10 countries.

    During the 20-week run-in, average weight fell by 10.6%. Over the next 48 weeks, those who continued lost a further 7.9%, while those switched to placebo regained 6.9%, a difference of 14.8 percentage points. Stomach and gut side effects were reported by 49.1% of those who continued and 26.1% of those on placebo.

    Read with care: Only people who tolerated the drug through the run-in were randomized, so the results apply to that group. The follow-up after switching was under a year. Funded by Novo Nordisk.

    JAMA (STEP 4, NCT03548987) · pubmed.ncbi.nlm.nih.gov

  11. Human trial2016

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% of the semaglutide group (108 of 1,648) and 8.9% of the placebo group (146 of 1,649), a hazard ratio of 0.74 (95% confidence interval 0.58 to 0.95).

    Full finding, who was studied, and limits

    Who: 3,297 adults with type 2 diabetes; 83% already had heart or blood vessel disease, chronic kidney disease, or both. Randomly assigned to injected semaglutide (two dose groups) or placebo for 104 weeks, on top of standard care.

    Cardiovascular death, non-fatal heart attack or non-fatal stroke occurred in 6.6% of the semaglutide group (108 of 1,648) and 8.9% of the placebo group (146 of 1,649), a hazard ratio of 0.74 (95% confidence interval 0.58 to 0.95). Non-fatal stroke was lower (1.6% against 2.7%). Deaths from cardiovascular causes were similar in both groups. Complications of diabetic eye disease (such as bleeding in the eye or need for laser treatment) were more common with semaglutide (hazard ratio 1.76, 95% confidence interval 1.11 to 2.78). More people on semaglutide stopped because of side effects, mainly stomach and gut effects.

    Read with care: The trial was designed to show semaglutide was not worse than placebo for the heart (non-inferiority), not to prove it was better. It lasted two years and had a modest number of events. The eye finding led to a warning on the label. Funded by Novo Nordisk.

    New England Journal of Medicine (SUSTAIN-6, NCT01720446) · pubmed.ncbi.nlm.nih.gov

  12. Animal study2015

    Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide

    The paper describes how semaglutide was designed starting from liraglutide.

    Full finding, who was studied, and limits

    Who: Laboratory receptor and albumin binding tests, and mini-pigs. Written by Novo Nordisk scientists.

    The paper describes how semaglutide was designed starting from liraglutide. Semaglutide differs from human GLP-1 at two positions and carries a fatty acid side chain on one lysine. It bound the GLP-1 receptor about three times less tightly than liraglutide but bound albumin more tightly. In mini-pigs its half-life in the blood after injection into a vein was 46.1 hours.

    Read with care: Laboratory and animal work by the maker's own scientists. It explains the design of the molecule. It says nothing about benefit or harm in people.

    Journal of Medicinal Chemistry · pubmed.ncbi.nlm.nih.gov

Safety findings

  • Boxed warning on the Ozempic, Rybelsus and Wegovy labels: in rodents, semaglutide caused thyroid C-cell tumors that increased with dose and length of treatment, at exposures relevant to people. The labels say it is unknown whether it causes such tumors, including medullary thyroid carcinoma (a type of thyroid cancer), in humans. It is contraindicated (must not be used) in people with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2. Source: dailymed.nlm.nih.gov
  • Most common side effects in the adult weight trials of the Wegovy injection (label table, 2,116 people on Wegovy against 1,261 on placebo, up to 68 weeks): nausea 44% against 16%; diarrhea 30% against 16%; vomiting 24% against 6%; constipation 24% against 11%; abdominal pain 20% against 10%; headache 14% against 10%; fatigue 11% against 5%; hair loss 3% against 1%. Side effects led 6.8% on Wegovy and 3.2% on placebo to stop treatment for good. Source: dailymed.nlm.nih.gov
  • Most common side effects in the placebo-controlled diabetes trials. Ozempic injection (two dose groups against placebo): nausea 15.8% and 20.3% against 6.1%; vomiting 5% and 9.2% against 2.3%; diarrhea 8.5% and 8.8% against 1.9%. Stomach and gut side effects led 3.1% and 3.8% to stop treatment, against 0.4% on placebo. Rybelsus tablets (two dose groups against placebo): nausea 11% and 20% against 6%; abdominal pain 10% and 11% against 4%; diarrhea 9% and 10% against 4%; decreased appetite 6% and 9% against 1%. Source: dailymed.nlm.nih.gov
  • Severe stomach and gut reactions, and gastroparesis (slow stomach emptying): the labels carry a warning on severe gastrointestinal adverse reactions, updated in October 2025. In the Wegovy injection trials, severe reactions of this kind were reported in 4.1% on Wegovy against 0.9% on placebo. The labels say semaglutide is not recommended in people with severe gastroparesis. Reports received after approval include ileus (the bowel stops moving food along), intestinal obstruction, and severe constipation including fecal impaction. Because these are voluntary reports, they do not show how often such events happen. Source: dailymed.nlm.nih.gov
8 more safety findings
  • Other warnings on the current labels: acute pancreatitis (inflammation of the pancreas); acute gallbladder disease; low blood sugar, mainly when combined with insulin or medicines that raise insulin; acute kidney injury linked to fluid loss; serious allergic reactions; worsening of diabetic eye disease in people with type 2 diabetes; a rise in heart rate; and food or liquid entering the lungs during general anesthesia or deep sedation. In the Wegovy injection trials, gallstones were reported in 1.6% against 0.7% on placebo, and resting heart rate rose by an average of 1 to 4 beats per minute. Source: dailymed.nlm.nih.gov
  • Diabetic eye disease: in the two-year SUSTAIN-6 trial in people with type 2 diabetes at high heart risk, complications of diabetic retinopathy (damage to the light-sensing layer of the eye) occurred in 3.0% on semaglutide and 1.8% on placebo. The difference was larger in people who already had retinopathy at the start (8.2% against 5.2%) than in those who did not (0.7% against 0.4%). Source: dailymed.nlm.nih.gov
  • Vision loss from NAION: on November 9, 2026 the FDA said it is requiring a new warning on all GLP-1 medicines, including Ozempic, Rybelsus and Wegovy, about a possible increased risk of non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition in which reduced blood flow to the optic nerve causes sudden, painless loss of vision in one eye. In the FDA's analysis of 126 randomized trials with 134,253 patients there were 15 probable cases: 10 on a GLP-1 medicine and 5 on placebo, or 6.4 against 3.8 cases per 100,000 person-years. In an FDA database study of adults with type 2 diabetes, the risk was higher than with one comparison class of diabetes medicines (hazard ratio 1.43, 95% confidence interval 1.02 to 2.01) and not significantly different from another (1.19, 0.91 to 1.54). The FDA described the condition as rare and found no explanation for it in animal data. The labels read for this page predate this announcement and did not yet carry the warning. Source: fda.gov
  • European regulator on NAION: on June 6, 2025 the European Medicines Agency's safety committee concluded that NAION is a very rare side effect of semaglutide medicines, meaning it may affect up to 1 in 10,000 people taking them. It said that in adults with type 2 diabetes, semaglutide was linked to about twice the risk of NAION compared with not taking it, equal to about one extra case per 10,000 person-years of treatment. Source: ema.europa.eu
  • Suicidal thoughts: on January 13, 2026 the FDA said its review found no increased risk of suicidal thoughts or behavior with GLP-1 medicines and asked for that warning to be removed from the Saxenda, Wegovy and Zepbound labels. The review included an analysis of 91 placebo-controlled trials with 107,910 patients, and a database study of more than 2.2 million new users that found no higher risk of intentional self-harm than with another class of diabetes medicine. The Wegovy label read for this page lists that warning as removed in February 2026. Source: fda.gov
  • Altered skin sensation with the higher-strength injection: the Wegovy label reports dysesthesia (skin sensitivity, pain or burning) in 22% of people on the higher-strength injection, 6% on the standard strength and 0.3% on placebo. When it approved the higher strength on March 19, 2026, the FDA said this effect generally went away on its own or after the dose was lowered, and that it was investigating further. Source: fda.gov
  • Pregnancy: the Wegovy label says semaglutide may cause harm to the fetus and, because it stays in the body for a long time, carries advice for prescribers about stopping it well ahead of a planned pregnancy. Source: dailymed.nlm.nih.gov
  • Unapproved and compounded products: as of May 31, 2026 the FDA had received 990 adverse event reports for compounded semaglutide, and said such reports are likely undercounted. It reported dosing errors with compounded injectable semaglutide, some leading to hospital stays, caused by patients measuring the wrong amount and by health professionals miscalculating. The FDA also reported counterfeit Ozempic and fraudulent compounded products in the US, and said semaglutide sold online as "for research purposes" has been sold directly to consumers. There are no human safety studies of "research use" semaglutide products. Source: fda.gov

Rules and status

FDA-approved prescription medicine as Ozempic, Rybelsus and Wegovy (Novo Nordisk). Compounded semaglutide is not FDA-approved. The FDA says semaglutide salts are different active ingredients, and treats semaglutide sold online as "for research use" as an unapproved drug.

The full history, with dates

Approvals (dates from the FDA's Drugs@FDA database unless stated). Ozempic injection: approved December 5, 2017 to improve blood sugar control in adults with type 2 diabetes; cardiovascular risk reduction in adults with type 2 diabetes and established cardiovascular disease added January 16, 2020 (approval letter read); a further indication approved January 28, 2025, which the current label gives as reducing the risk of kidney function decline, kidney failure and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Rybelsus tablets: approved September 20, 2019 for blood sugar control in adults with type 2 diabetes; a new indication approved October 17, 2025, which the current label gives as cardiovascular risk reduction in adults with type 2 diabetes at high risk. The current tablet label (revised January 2026) also covers a second tablet version sold under the Ozempic name. Wegovy injection: approved June 4, 2021 for weight management; extended to a new patient group on December 23, 2022 (the label covers ages 12 and older with obesity); cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight approved March 8, 2024 (FDA announcement); MASH with moderate to advanced liver scarring approved August 15, 2025 under accelerated approval, which depends on later confirmation of benefit; a higher-strength version (Wegovy HD) approved March 19, 2026 for adults (FDA announcement). Wegovy tablets: approved December 22, 2025 for weight reduction and cardiovascular risk reduction in adults (approval letter read). All labels carry a boxed warning on thyroid C-cell tumors. On November 9, 2026 the FDA required all GLP-1 labels to add a warning on the eye condition NAION. Shortage and compounding: the FDA's declaratory order states that Wegovy was added to its drug shortage list on March 31, 2022 and Ozempic on August 23, 2022, which allowed wider compounding. On February 21, 2025 the FDA determined the shortage was resolved. It gave state-licensed pharmacies and physicians (503A) until April 22, 2025 and outsourcing facilities (503B) until May 22, 2025, later tied to a court ruling. On April 24, 2025 a federal district court in Texas denied the compounders' request for a preliminary injunction; the FDA then said the 503A period had ended and the 503B period would end May 22, 2025. The FDA's page (current as of April 1, 2026) says semaglutide is on neither the drug shortage list nor the 503B bulks list, so outsourcing facilities may not compound from bulk semaglutide, and 503A pharmacies fall under the rule against making what are essentially copies of an approved drug. Salt forms: the FDA says semaglutide sodium and semaglutide acetate are different active ingredients from the one in the approved medicines, that it has no information showing they share the same properties, and that it is not aware of any lawful basis for using them in compounding. 2026 actions: February 6, 2026, the FDA announced it intends to restrict GLP-1 ingredients used in non-approved compounded drugs that are mass-marketed, and said such products cannot be described as generic or the same as approved drugs. March 3, 2026, it announced 30 warning letters to telehealth companies. April 30, 2026, it proposed not to include semaglutide, tirzepatide and liraglutide on the 503B bulks list, finding no clinical need; this was published in the Federal Register on May 1, 2026 (91 FR 23431) and the comment period was extended to July 30, 2026 (91 FR 38719). No final decision was found as of November 18, 2026 (the FDA's compounding policies page, current as of September 9, 2026, lists only the proposal). "Research use" products: the FDA's page (current as of October 1, 2026) says it has warned companies selling unapproved semaglutide falsely labeled "for research purposes" or "not for human consumption", and urges consumers not to buy them. For example, a warning letter dated August 24, 2026 to Royal Peptides LLC named a semaglutide product and stated that the website evidence established the products were intended to be drugs for human use, despite the "research use only" wording. HHS peptide policy: semaglutide is not among the six peptides named in the HHS draft enforcement-discretion policy announced on October 30, 2026 (91 FR 68526); Appendix A of the policy (on hhs.gov, read from an Internet Archive capture of November 15, 2026) names exactly BPC-157, epitalon, KPV, MOTS-c, semax and TB-500.

Source: fda.gov (source dated 2026-10-01)

In sport: Not on the WADA Prohibited List: semaglutide is not named in the 2026 List (in force from January 1, 2026) or the 2027 List (in force from January 1, 2027). Class S0 (Non-approved substances) does not catch it, because S0 covers only substances 'with no current approval by any governmental regulatory health authority for human therapeutic use', and semaglutide is FDA-approved. It is on the WADA Monitoring Program, which tracks substances that are not banned in order to detect patterns of misuse: listed as 'Semaglutide' for 2024 and 2025, as 'Markers of semaglutide and tirzepatide' for 2026, and as 'GLP-1 agonists: semaglutide and tirzepatide' for 2027, in and out of competition each year. When WADA published the 2027 List on September 21, 2026, it said the status of GLP-1 receptor agonists, including semaglutide, remains unchanged for 2027 pending more data, that there was not yet enough evidence to conclude they meet the criteria for a ban, and that it has two studies in athletes under way. WADA

Claims and what the evidence supports

What people sayWhat the evidence supports
Research-grade semaglutide sold online is the same thing as Ozempic or Wegovy.The FDA says these are unapproved drugs, falsely labeled "for research purposes" or "not for human consumption", and urges consumers not to buy them. It has sent warning letters to sellers. None of the trials on this page tested these products. Source: fda.gov
Compounded semaglutide is a generic or FDA-approved version.Compounded drugs are not FDA-approved. In February 2026 the FDA said companies cannot claim compounded products are generic versions of, or the same as, approved drugs. The shortage that had allowed wider compounding was declared resolved on February 21, 2025. Source: fda.gov
Semaglutide sodium or semaglutide acetate is the same ingredient as the approved medicine.The FDA says these salt forms are different active ingredients from the one used in the approved medicines, that it has no information showing they have the same chemical and pharmacologic properties, and that it knows of no lawful basis for using them in compounding. Source: fda.gov
The weight stays off once you stop.In STEP 4, people switched to placebo after 20 weeks regained 6.9% of their body weight over the next 48 weeks, while those who continued lost a further 7.9%. In the STEP 1 extension, people had regained about two-thirds of their lost weight one year after stopping. Source: pubmed.ncbi.nlm.nih.gov
The weight lost is all fat.The FDA label says semaglutide lowered body weight with a greater loss of fat mass than of lean mass. That means some lean mass (which includes muscle) was lost too. The exact proportions were not read for this page. Source: dailymed.nlm.nih.gov
It protects the heart.Supported in specific groups. In SELECT (17,604 adults who already had heart or blood vessel disease plus overweight or obesity), major heart events occurred in 6.5% on semaglutide and 8.0% on placebo. Trials in type 2 diabetes pointed the same way. It has not been tested for this in people without existing disease or high risk. Source: pubmed.ncbi.nlm.nih.gov
It protects the brain or helps with Alzheimer's disease.Not supported by the trials so far. In two phase 3 trials of 3,808 people with early Alzheimer's disease, semaglutide tablets did not slow decline over 104 weeks compared with placebo, and the trials were stopped. Source: pubmed.ncbi.nlm.nih.gov
It makes people go blind.The FDA and the European regulator have both linked GLP-1 medicines to a possible increased risk of NAION, a condition that can cause sudden vision loss in one eye, and both describe it as rare. In the FDA's pooled trial analysis there were 6.4 cases per 100,000 person-years on a GLP-1 medicine against 3.8 on comparison treatments. A separate label warning covers worsening of existing diabetic eye disease. Source: fda.gov
It paralyzes the stomach.The label says semaglutide delays stomach emptying and is not recommended in people with severe gastroparesis. Severe stomach and gut reactions were reported in 4.1% on the Wegovy injection against 0.9% on placebo. Blocked or stalled bowel has been reported after approval, but those reports do not show how often it happens. Source: dailymed.nlm.nih.gov
It is banned in sport.It is not on the WADA Prohibited List. WADA has monitored its use since 2024 and said in September 2026 that there was not yet enough evidence to decide whether it meets the criteria for a ban. Source: wada-ama.org

What a genuine lab report should show

  • Identity by mass spectrometry: the measured mass should match semaglutide's expected molecular weight of about 4113.6 Da (FDA label: 4113.58 g/mol; PubChem monoisotopic mass: 4111.115 Da). A report that shows a different mass, or no mass data, does not confirm identity.
  • Base or salt: the report should say plainly whether the material is semaglutide itself or a salt such as semaglutide sodium or semaglutide acetate. The FDA says the salt forms are different active ingredients from the one in the approved medicines.
  • Purity by HPLC (a method that separates a sample into its components), with the actual chromatogram shown, the purity percentage, and any impurity peaks listed. Semaglutide is a 31-amino-acid peptide with a non-standard amino acid and a fatty acid side chain, so incomplete or mis-built chains are a realistic impurity.
  • Content: the measured amount of peptide in the vial compared with the amount on the label. The FDA has reported counterfeit and fraudulent semaglutide products, and has said counterfeit drugs can contain too little, too much, or none of the active ingredient.
  • Traceability: the report should name the testing laboratory, the lot or batch number, and the test date, and the lot number should match the product.
  • What a lab report cannot do: a certificate of analysis does not make a product FDA-approved, and it does not show the product is sterile or safe unless those tests were actually run and reported. The approved medicines are made under FDA oversight; "research use" products are not.

How to read a lab report

What is not known

  • Whether the thyroid C-cell tumors seen in rodents are relevant to humans. The labels say this has not been determined.
  • How large the NAION risk really is. The FDA's pooled trial analysis rests on 15 probable cases, its database study gave a clear signal against one comparison medicine but not another, and the European regulator's estimate (about one extra case per 10,000 person-years) is higher than the difference in the FDA's trial analysis. The exact wording of the new US label warning had not appeared in the labels read for this page.
  • Whether the liver benefit seen on biopsy at 72 weeks turns into fewer liver transplants, liver failures or deaths. The trial runs to 240 weeks and the approval is conditional on it.
  • Long-term effects of the higher-strength injection, including the altered skin sensation that the FDA says it is still investigating.
  • The FDA's April 30, 2026 proposal to keep semaglutide off the 503B bulks list: no final decision was found as of November 18, 2026.
  • WADA has said a decision on GLP-1 medicines depends on studies in athletes that are still running. The status could change in a future list.
  • How much of the weight lost is lean mass, and what that means for strength and function. The label says only that fat loss was greater than lean mass loss; the body-scan substudies were not read for this page.
  • The FDA's count of adverse event reports for compounded semaglutide (990 as of May 31, 2026) is not a rate and cannot show cause; the true number of harms is unknown.
  • The exact dates on which the kidney indication (Ozempic) and the cardiovascular indication (Rybelsus) were approved are taken from Drugs@FDA database entries that say only 'new indication'; the approval letters for those two supplements were not read.

Sources

All 48 sources
  1. PubChem: Semaglutide (CID 56843331). pubchem.ncbi.nlm.nih.gov
  2. DailyMed: Wegovy injection and tablets prescribing information (revised 6/2026). dailymed.nlm.nih.gov
  3. DailyMed: Ozempic injection prescribing information (revised 5/2026). dailymed.nlm.nih.gov
  4. DailyMed: Rybelsus and Ozempic tablets prescribing information (revised 1/2026). dailymed.nlm.nih.gov
  5. Drugs@FDA: Ozempic injection, NDA 209637 (approval history). accessdata.fda.gov
  6. Drugs@FDA: Rybelsus and Ozempic tablets, NDA 213051 (approval history). accessdata.fda.gov
  7. Drugs@FDA: Wegovy injection, NDA 215256 (approval history). accessdata.fda.gov
  8. Drugs@FDA: Wegovy tablets, NDA 218316 (approval history). accessdata.fda.gov
  9. FDA approval letter: Ozempic cardiovascular indication (January 16, 2020). accessdata.fda.gov
  10. FDA approval letter: Wegovy tablets, NDA 218316. accessdata.fda.gov
  11. FDA approval letter: Wegovy supplement 23, heart failure endpoint description (not a new indication). accessdata.fda.gov
  12. FDA news release: Wegovy approved to reduce risk of serious heart problems (March 8, 2024). fda.gov
  13. FDA: Wegovy approved for the liver disease MASH (page dated August 15, 2025). fda.gov
  14. FDA press announcement: higher-strength semaglutide (Wegovy HD) approved (March 19, 2026). fda.gov
  15. FDA Drug Safety Communication: NAION labeling change for GLP-1 medicines (November 9, 2026). fda.gov
  16. FDA Drug Safety Communication: removal of suicidal behavior and ideation warning (January 13, 2026). fda.gov
  17. EMA: PRAC concludes NAION is a very rare side effect of semaglutide medicines (June 6, 2025). ema.europa.eu
  18. FDA declaratory order: resolution of semaglutide injection shortages (February 21, 2025). fda.gov
  19. FDA: policies for compounders as GLP-1 supply stabilizes (current as of April 1, 2026). fda.gov
  20. FDA: concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026). fda.gov
  21. FDA press statement: intent to act against non-FDA-approved GLP-1 drugs (February 6, 2026). fda.gov
  22. FDA press announcement: 30 telehealth companies warned over compounded GLP-1 marketing (March 3, 2026). fda.gov
  23. FDA press announcement: proposal to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026). fda.gov
  24. Federal Register (FDA notice): 503B bulks list proposal, 91 FR 23431 (May 1, 2026). federalregister.gov
  25. Federal Register (FDA notice): extension of comment period to July 30, 2026, 91 FR 38719. federalregister.gov
  26. FDA: Human Drug Compounding Policies and Rules (current as of September 9, 2026). fda.gov
  27. FDA warning letter: Royal Peptides LLC (August 24, 2026). fda.gov
  28. WADA 2027 Prohibited List, published 21 September 2026, in force 1 January 2027. wada-ama.org
  29. WADA: 2027 Monitoring Program. wada-ama.org
  30. WADA: 2026 Monitoring Program. wada-ama.org
  31. WADA: 2025 Monitoring Program. wada-ama.org
  32. WADA: 2024 Monitoring Program. wada-ama.org
  33. WADA: 2026 Prohibited List. wada-ama.org
  34. Lau et al. 2015, J Med Chem (discovery of semaglutide). pubmed.ncbi.nlm.nih.gov
  35. Marso et al. 2016, NEJM (SUSTAIN-6). pubmed.ncbi.nlm.nih.gov
  36. Wilding et al. 2021, NEJM (STEP 1). pubmed.ncbi.nlm.nih.gov
  37. Rubino et al. 2021, JAMA (STEP 4). pubmed.ncbi.nlm.nih.gov
  38. Wilding et al. 2022, Diabetes Obes Metab (STEP 1 extension). pubmed.ncbi.nlm.nih.gov
  39. Lincoff et al. 2023, NEJM (SELECT). pubmed.ncbi.nlm.nih.gov
  40. Perkovic et al. 2024, NEJM (FLOW). pubmed.ncbi.nlm.nih.gov
  41. SOUL trial 2025, NEJM (semaglutide tablets, cardiovascular outcomes). pubmed.ncbi.nlm.nih.gov
  42. ESSENCE trial 2025, NEJM (MASH). pubmed.ncbi.nlm.nih.gov
  43. Wharton et al. 2025, NEJM (OASIS 4, semaglutide tablets for obesity). pubmed.ncbi.nlm.nih.gov
  44. STEP UP trial 2025, Lancet Diabetes Endocrinol (higher-dose injection). pubmed.ncbi.nlm.nih.gov
  45. STEP UP T2D trial 2025, Lancet Diabetes Endocrinol (higher-dose injection, type 2 diabetes). pubmed.ncbi.nlm.nih.gov
  46. Cummings et al. 2026, Lancet (evoke and evoke+, Alzheimer's disease). pubmed.ncbi.nlm.nih.gov
  47. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (the six peptides) and Appendix B (HHS reasoning); read from an Internet Archive capture of 15 November 2026. hhs.gov
  48. Federal Register, 30 October 2026, 91 FR 68526: HHS notice of the draft enforcement discretion policy. govinfo.gov

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.